Elevated urinary CXCL10-to-creatinine ratio is associated with subclinical and clinical rejection in pediatric renal transplantation

Transplantation

Volumn 99, Issue 4, 2015, Pages 797-804

  Blydt Hansen, Tom D ^a   Gibson, Ian W ^a   Gao, Ang ^b   Dufault, Brenden ^a   Ho, Julie ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CREATININE; CYCLOSPORIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MYCOPHENOLATE MOFETIL; TACROLIMUS; THYMOCYTE ANTIBODY; BIOLOGICAL MARKER; CXCL10 PROTEIN, HUMAN;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ARTICLE; CHILD; CONTROLLED STUDY; CREATININE URINE LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ATROPHY; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; TUBULITIS; URINARY CXCL10 TO CREATININE RATIO; UROGENITAL SYSTEM PARAMETERS; VALIDATION STUDY; ACUTE DISEASE; ADOLESCENT; ADVERSE EFFECTS; AGE; AREA UNDER THE CURVE; ASYMPTOMATIC DISEASE; BIOPSY; GRAFT REJECTION; IMMUNOLOGY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROSPECTIVE STUDY; REPRODUCIBILITY; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UPREGULATION; URINE;

ACUTE DISEASE; ADOLESCENT; AGE FACTORS; AREA UNDER CURVE; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; BIOPSY; CHEMOKINE CXCL10; CHILD; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; ROC CURVE; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84930182290     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000419     Document Type: Article

References (31)

1. North American Pediatric Renal Trials and Collaborative Studies. NAPRTCS 2010 Annual Transplant Report. Boston, MA: Emmes Corporation; 2010.
2. Hymes LC, Greenbaum L, Amaral SG, et al. Surveillance renal transplant biopsies and subclinical rejection at three months post-transplant in pediatric recipients. Pediatr Transplant. 2007;11:536.
3. Hymes LC, Warshaw BL, Hennigar RA, et al. Prevalence of clinical rejection after surveillance biopsies in pediatric renal transplants: does early subclinical rejection predispose to subsequent rejection episodes? Pediatr Transplant. 2009;13:823.
4. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157.
5. Dart AB, Schall A, Gibson IW, et al. Patterns of chronic injury in pediatric renal allografts. Transplantation. 2010;89:334.
6. Nickerson P, Jeffery J, Gough J, et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol. 1998;9:482.
7. Birk PE, Stannard KM, Konrad HB, et al. Surveillance biopsies are superior to functional studies for the diagnosis of acute and chronic renal allograft pathology in children. Pediatr Transplant. 2004;8:29.
8. Hoffmann SC, Hale DA, Kleiner DE, et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant. 2005;5:573.
9. Reeve J, Einecke G, Mengel M, et al. Diagnosing rejection in renal transplants: a comparison of molecular-and histopathology-based approaches. Am J Transplant. 2009;9:1802.
10. el-Sawy T, Fahmy NM, Fairchild RL. Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol. 2002;14:562.
11. Kanmaz T, Feng P, Torrealba J, et al. Surveillance of acute rejection in baboon renal transplantation by elevation of interferon-gamma inducible protein-10 and monokine induced by interferon-gamma in urine. Transplantation. 2004;78:1002.
12. Tatapudi RR, Muthukumar T, Dadhania D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int. 2004;65:2390.
13. Ho J, Rush DN, Gibson IW, et al. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation. 2010;90:394.
14. Matz M, Beyer J, Wunsch D, et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short-and longterm graft function. Kidney Int. 2006;69:1683.
15. Hauser IA, Spiegler S, Kiss E, et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol. 2005;16:1849.
16. Ho J, Rush DN, Karpinski M, et al. Validation of urinary CXCL10 as amarker of borderline, subclinical, and clinical tubulitis. Transplantation. 2011;92:878.
17. Hu H, Kwun J, Aizenstein BD, et al. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation. 2009;87:1814.
18. Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant. 2011;11:2228.
19. Schaub S, Nickerson P, Rush D, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant. 2009;9:1347.
20. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272.
21. Hricik DE, Nickerson P, Formica RN, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant. 2013;13:2634.
22. Suthanthiran M, Schwartz JE, Ding R, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med. 2013;369:20.
23. Hirt-Minkowski P, Amico P, Ho J, et al. Detection of clinical and subclinical tubulo-interstitial inflammation by the urinary CXCL10 chemokine in a reallife setting. Am J Transplant. 2012;12:1811.
24. Tay SS, McCormack A, RoseML. Effect of cognate human CD4+ Tcell and endothelial cell interactions upon chemokine production. Transplantation. 2004;78:987.
25. Naemi FM, Carter V, Kirby JA, et al. Anti-donor HLA class I antibodies: pathways to endothelial cell activation and cell-mediated allograft rejection. Transplantation. 2013;96:258.
26. Gomez-Chiarri M, Hamilton TA, Egido J, et al. Expression of IP-10, a lipopolysaccharide-and interferon-gamma-inducible protein, in murine mesangial cells in culture. Am J Pathol. 1993;142:433.
27. Lazzeri E, Romagnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5:109.
28. Sterzel RB, Schulze-Lohoff E, Marx M. Cytokines and mesangial cells. Kidney Int Suppl. 1993;39:S26.
29. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007;7:518.
30. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4:1832.
31. Akcan-Arikan A, Zappitelli M, Loftis LL, et al. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71:1028.